Latest news

• Pfizer closes on EU approval of lung cancer drug Vizimpro

  The CHMP also backed Teva’s CGRP inhibitor Ajovy (fremanezumab) for migraine prevention, setting the drug on course to compete with earlier approvals Aimovig (erenumab) from Amgen/Novartis and Emgality (galcanezumab)

• NICE rejects Novartis migraine treatment Aimovig

  Novartis has a number of competitors in the CGRP class hot on its heels: Lilly's Emgality (galcanezumab) gained EU approval in November, and is now entering the NICE appraisal process.

• Teva wins FDA OK for crucial migraine drug

  ahead of late-stage rivals from Eli Lilly (galcanezumab) and Alder Biopharma (eptinezumab).

• First migraine prevention drug to hit European market

  The treatment seems to be off to a promising start, storming well ahead of rival treatments from Eli Lilly’s galcanezumab, Teva’s fremanezumab and Alder's eptinezumab.

• CGRP migraine drugs need prior approval for use, recommends ICER

  s fremanezumab and Eli Lilly’s galcanezumab are used prudently. ... Fremanezumab and galcanezumab remain under FDA review but should have decisions before year-end, will also be priced around the same level as Aimovig.